Reaction
Pancreatic Neuroendocrine Tumour reporting signals
As of the last recalculation, Pancreatic Neuroendocrine Tumour appears in 633 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 263.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Octreotide Acetate | 177 | 263.4 | 264.9 |
| Everolimus | 175 | 155.9 | 156.5 |
| Everolimus Tablets | 53 | 113.3 | 113.7 |
| Sunitinib Malate | 79 | 75.3 | 75.5 |
| Lanreotide Acetate | 12 | 51.3 | 51.4 |
| Esomeprazole Magnesium Capsule, Delayed Release | 17 | 39.6 | 39.6 |
| Esomeprazole Magnesium Delayed Release Capsules | 17 | 39.6 | 39.6 |
| Esomeprazole Magnesium Dihydrate | 17 | 39.4 | 39.4 |
| Temozolomide | 23 | 37.2 | 37.2 |
| Capecitabine | 49 | 19.0 | 19.0 |
| Exenatide | 27 | 17.6 | 17.6 |
| Liraglutide | 23 | 15.8 | 15.9 |